Silyvit-E

• Liver disease
• Fatty Liver Syndrome
• Liver cirrhosis
• Cholestatic liver disease
• Non-alcoholic fatty liver disease (NAFLD)

This preparation is indicated for the treatment and prevention of-

• Liver disease (non-alcoholic & alcoholic)

• Fatty liver (non-alcoholic & alcoholic)

• Hepatitis

• Liver cirrhosis (non-alcoholic & alcoholic)

• Jaundice

• Liver fibrosis

• Drug-induced hepatotoxicity

N/A

Contraindicated in patient with a known hypersensitivity to silymarin & vitamin E.

Silymarin, a flavonoid complex of Milk thistle, is the biologically active component. Silymarin is well known hepatoprotective agent. It is prepared with standardized extract of Milk Thistle fruits. Silymarin stimulates RNA polymerase-A, enhances protein synthesis and helps to regenerate and repair liver cell. It prevents toxic and foreign substances from penetrating into the liver cells by stabilizing the outer mem- brane of liver cells. Silymarin also acts by anti-lipid peroxidative, antifibrotic, anti-inflammatory, membrane stabilizing, immunomodulatory and liver regenerating mechanisms. Dl-alpha tocopherol acetate (Vitamin E) is a tocol which is one of the most potent anti- oxidant tocopherols. It exhibits antioxidant activity by virtue of the phenolic hydrogen on the 2H-1-benzopyran-6-ol nucleus. Vitamin E has powerful antioxidant properties which can provide numerous benefits to the body, and may protect cells from oxidative damage.

Concomitant use of silymarin and butyrophenones or phenothiazines has resulted in the reduction of lipid peroxidation.

Well tolerated in recommended dose. Occasionally a mild laxative effect may observe.